Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.
Humans
Cross-Sectional Studies
Female
Granulocyte Colony-Stimulating Factor
/ therapeutic use
Surveys and Questionnaires
Middle Aged
Male
Practice Patterns, Physicians'
/ statistics & numerical data
Adult
Aged
Lung Neoplasms
/ drug therapy
Breast Neoplasms
/ drug therapy
Ambulatory Care
/ methods
Neoplasms
/ drug therapy
Outpatients
/ statistics & numerical data
Breast cancer
Chemotherapy
Febrile neutropenia
G-CSF
Gastrointestinal cancer
Lung cancer
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
22
11
2023
accepted:
24
04
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
This study aims to delineate G-CSF treatment practices, assess decision criteria, and measure their implementation in ambulatory settings for patients with breast (BC), lung (LC), or gastrointestinal cancers (GIC), beyond standard recommendations. In this non-interventional, cross-sectional, multicenter study, clinical cases were presented using conversational interfaces (chatbots), simulating a conversation with one or more virtual interlocutors through voice or text exchange. The clinical simulations were configured by four parameters: types of cancer, risk of FN related to chemotherapy and comorbidities, access to care, and therapy setting (adjuvant/neoadjuvant/metastatic). The questionnaire was completed by 102 physicians. Most practitioners (84.5%) reported prescribing G-CSF, regardless of tumor type. G-CSF was prescribed more frequently for adjuvant/neoadjuvant therapy than for metastatic cases. The type of chemotherapy was cited as the first reason for prescribing G-CSF, with access to care being the second. Regarding the type of chemotherapy, physicians do not consider this factor alone, but combined with comorbidities and age (56.7% of cases). Pegfilgrastim long-acting was prescribed in most cases of BC and LC (70.1% and 86%, respectively), while filgrastim short-acting was named in the majority of cases of GIC (61.7%); 76.3% of physicians prescribed G-CSF as primary prophylaxis. Our findings suggest that recommended practices are broadly followed. In the majority of cases, G-CSF is prescribed as primary prophylaxis. In addition, physicians seem more inclined to prescribe G-CSF to adjuvant/neoadjuvant patients rather than metastatic patients. Finally, the type of chemotherapy tends to be a more significant determining factor than the patient's background.
Identifiants
pubmed: 38743147
doi: 10.1007/s00520-024-08524-0
pii: 10.1007/s00520-024-08524-0
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
347Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Patel K, West HJ (2017) Febrile neutropenia. JAMA. Oncol 3(12):1751
Punnapuzha S, Edemobi PK, Elmoheen A (2023) Febrile Neutropenia. Treasure Island: StatPearls Publishing
Ropka ME, Padilla G (2007) Assessment of neutropenia-related quality of life in a clinical setting. Oncol Nurs Forum 34(2):403–409
doi: 10.1188/07.ONF.403-409
pubmed: 17573304
Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H et al (2015) Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 11(1):47–54
doi: 10.1200/JOP.2014.001492
pubmed: 25491042
Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404
doi: 10.1186/1471-2407-11-404
pubmed: 21943360
pmcid: 3203098
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC Growth Factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199–3212
doi: 10.1200/JCO.2015.62.3488
pubmed: 26169616
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32
doi: 10.1016/j.ejca.2010.10.013
pubmed: 21095116
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P et al (2017) Myeloid growth factors, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(12):1520–41
doi: 10.6004/jnccn.2017.0175
pubmed: 29223990
Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M et al (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v111–v118
doi: 10.1093/annonc/mdw325
pubmed: 27664247
Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R et al (2022) NCCN guidelines(R) insights: hematopoietic growth factors, Version 1.2022. J Natl Compr Canc Netw 20(5):436–42
doi: 10.6004/jnccn.2022.0026
pubmed: 35545171
Kelly S, Wheatley D (2009) Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer 101(Suppl 1(Suppl 1)):S6-10
doi: 10.1038/sj.bjc.6605269
pubmed: 19756005
pmcid: 2752223
Barnes G, Pathak A, Schwartzberg L (2014) G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med 3(6):1477–1484
doi: 10.1002/cam4.344
pubmed: 25410813
pmcid: 4298373
Link H, Nietsch J, Kerkmann M, Ortner P, Supportive Care Group of the German Cancer S (2016) Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy–a representative sample survey in Germany. Support Care Cancer 24(1):367–76
doi: 10.1007/s00520-015-2779-5
pubmed: 26081593
Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40(3):402–407
doi: 10.1345/aph.1G516
pubmed: 16492793
Scotte F, Simon H, Laplaige P, Antoine EC, Spasojevic C, Texier N et al (2021) Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment. BMJ Support Palliat Care. https://doi.org/10.1136/bmjspcare-2021-003082
Borget I, Antoun S, Chachaty E, Gachot B, Alibay A, Di Palma M et al (2014) Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs. Bull Cancer 101(10):925–931
doi: 10.1684/bdc.2014.1958
pubmed: 25373692
Gebremariam GT, Fentie AM, Beyene K, Sander B, Gebretekle GB (2022) Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. BMC Health Serv Res 22(1):1600
doi: 10.1186/s12913-022-08933-z
pubmed: 36585648
pmcid: 9805270
Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascon P, Denhaerynck K et al (2019) Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. Future Oncol 15(8):897–907
doi: 10.2217/fon-2018-0814
pubmed: 30827127
Aapro M, Krendyukov A, Hobel N, Gascon P (2019) Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: results from the MONITOR-GCSF study. Eur J Cancer Care (Engl) 28(4):e13034
doi: 10.1111/ecc.13034
pubmed: 30968997
Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6(2):109–118
doi: 10.6004/jnccn.2008.0012
pubmed: 18319047
Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M (2000) Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA 283(13):1715–1722
doi: 10.1001/jama.283.13.1715
pubmed: 10755498
Peabody JW, Luck J, Glassman P, Jain S, Hansen J, Spell M et al (2004) Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med 141(10):771–780
doi: 10.7326/0003-4819-141-10-200411160-00008
pubmed: 15545677
Petrelli F, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M et al (2018) Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 103:7–16
doi: 10.1016/j.ejca.2018.07.129
pubmed: 30196108
Buske C, Dreyling M, Alvarez-Larran A, Apperley J, Arcaini L, Besson C et al (2022) Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open 7(2):100403
doi: 10.1016/j.esmoop.2022.100403
pubmed: 35272130
pmcid: 8795783
Aapro M, Lyman GH, Bokemeyer C, Rapoport BL, Mathieson N, Koptelova N et al (2021) Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open 6(1):100038
doi: 10.1016/j.esmoop.2020.100038
pubmed: 33421735